Celera gene rights from Variagenics:
This article was originally published in Clinica
Celera Diagnostics has licensed gene rights from molecular diagnostics and pharmacogenomics firm Variagenics for applications including assessment of thromboembolic disease risk. The patents cover the identification of polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, which is believed to be involved in cardiovascular, central nervous system and folic acid metabolism disorders as well as cancer and osteoporosis. Celera's products are expected to be sold as analyte specific reagents and maybe later as in vitro diagnostic devices.